This will be the company’s research, development, and manufacturing base.
The investment was enabled by a 10-year partnership with the UK government – managed by the UK Health Security Agency. The first product expected to be manufactured at scale on the site will be the COVID-19 vaccine to support the NHS vaccination programme.
Advanced Research and Vaccine Production
MITC will also feature labs and offices to support high-priority pre-clinical and clinical-stage testing.
Darius Hughes, general manager of Moderna UK, said: “We have made remarkable progress since initiating our unique strategic partnership with the UK government two years ago. Later this year, this state-of-the-art facility will be ready to deliver British-made Covid-19 vaccines, ensuring a robust supply for the UK public.”
